拓新药业
(301089)
| 流通市值：30.32亿 | | | 总市值：42.18亿 |
| 流通股本：9097.55万 | | | 总股本：1.27亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 207,432,231.98 | 177,469,963.24 | 292,747,146.46 | 148,553,750.34 |
| 应收票据及应收账款 | 101,620,252.9 | 114,912,496.17 | 122,330,574.36 | 203,339,038.92 |
| 其中：应收票据 | 13,525,758.3 | 14,825,505.53 | 18,356,752.87 | 51,661,058.82 |
| 应收账款 | 88,094,494.6 | 100,086,990.64 | 103,973,821.49 | 151,677,980.1 |
| 应收款项融资 | 51,961,320.63 | 72,717,092.93 | 62,385,289.55 | 31,957,118.51 |
| 预付款项 | 9,393,961.26 | 6,239,530.91 | 10,537,661.19 | 4,262,516.92 |
| 其他应收款合计 | 146,846.99 | 70,619.3 | 150,610.62 | 46,960.81 |
| 存货 | 162,787,548.1 | 172,589,664.46 | 187,947,995.73 | 204,110,789.91 |
| 其他流动资产 | 14,734,263.32 | 40,816,013.12 | 39,329,805.61 | 39,194,604.83 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 698,317,762.17 | 734,975,599.31 | 785,429,083.52 | 822,169,778.54 |
| 非流动资产: | | | | |
| 长期股权投资 | 2,050,893.45 | 1,451,146.77 | 1,450,893.45 | 1,450,893.45 |
| 其他权益工具投资 | 6,921,006.21 | 6,921,006.21 | 6,921,006.21 | 6,921,006.21 |
| 固定资产 | 452,065,839.62 | 460,871,777.94 | 470,245,886.92 | 478,348,414.04 |
| 在建工程 | 376,293,699.42 | 364,148,968.75 | 359,986,115.94 | 331,031,336.05 |
| 无形资产 | 81,286,853.18 | 82,205,210.78 | 83,123,568.39 | 84,041,925.97 |
| 长期待摊费用 | 2,683,412.23 | 2,336,501.8 | 2,433,353.24 | 2,702,907.82 |
| 递延所得税资产 | 71,416,621.95 | 62,798,276.13 | 63,147,981.86 | 63,705,501.66 |
| 其他非流动资产 | 55,553,589.62 | 52,920,704.41 | 46,130,569.7 | 48,622,798.24 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,048,271,915.68 | 1,033,653,592.79 | 1,033,439,375.71 | 1,016,824,783.44 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,746,589,677.85 | 1,768,629,192.1 | 1,818,868,459.23 | 1,838,994,561.98 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 114,640,269.76 | 131,864,462.14 | 148,006,399.11 | 152,548,234.96 |
| 其中：应付票据 | 34,431,715.38 | 39,376,827.03 | 40,783,626.98 | 42,159,549.27 |
| 应付账款 | 80,208,554.38 | 92,487,635.11 | 107,222,772.13 | 110,388,685.69 |
| 合同负债 | 845,432.83 | 555,879.54 | 956,586.92 | 5,482,986.93 |
| 应付职工薪酬 | 8,351,747.95 | 8,295,783.62 | 8,108,042.26 | 18,304,515.79 |
| 应交税费 | 2,801,674.75 | 2,898,756.35 | 3,207,853.98 | 2,821,805.47 |
| 其他应付款合计 | 3,943,959.75 | 3,894,307.51 | 1,529,626.94 | 3,646,301.48 |
| 其他流动负债 | 7,866,449.42 | 11,139,550.43 | 10,479,376.57 | 11,708,395.75 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 138,449,534.46 | 158,648,739.59 | 172,287,885.78 | 194,512,240.38 |
| 非流动负债: | | | | |
| 递延收益 | 33,751,130.33 | 34,565,212.76 | 35,379,295.19 | 35,173,175.6 |
| 递延所得税负债 | 5,407,048.59 | 5,558,819.24 | 5,861,027.83 | 6,037,277.4 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 39,158,178.92 | 40,124,032 | 41,240,323.02 | 41,210,453 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 177,607,713.38 | 198,772,771.59 | 213,528,208.8 | 235,722,693.38 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 126,544,500 | 126,544,500 | 126,544,500 | 126,544,500 |
| 资本公积 | 621,109,964.85 | 621,109,964.85 | 621,109,964.85 | 621,109,964.85 |
| 其他综合收益 | 1,440,754.65 | 1,440,754.65 | 1,440,754.65 | 1,440,754.65 |
| 盈余公积 | 65,222,535.36 | 65,222,535.36 | 65,222,535.36 | 65,222,535.36 |
| 未分配利润 | 754,664,209.61 | 755,538,665.65 | 791,022,495.57 | 788,954,113.74 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,568,981,964.47 | 1,569,856,420.51 | 1,605,340,250.43 | 1,603,271,868.6 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,568,981,964.47 | 1,569,856,420.51 | 1,605,340,250.43 | 1,603,271,868.6 |
| 负债和股东权益合计 | 1,746,589,677.85 | 1,768,629,192.1 | 1,818,868,459.23 | 1,838,994,561.98 |
| 公告日期 | 2024-10-26 | 2024-08-24 | 2024-04-23 | 2024-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |